Drug Trial Radar · NCT05433285
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
Last checked: Nov 20, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,050
Actual
Start
Jun 7, 2022
Primary completion
Aug 5, 2022
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- PT Bio FarmaIndustry
- Sponsor type
- Industry
- Collaborators
- Fakultas Kedokteran Universitas Indonesia; Faculty of Medicine Universitas Diponegoro; Andalas University; Faculty of Medicine Universitas Hassanudin
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Observer-blind, randomized, active-controlled prospective intervention study
Conditions
- COVID-19
Interventions
COVID-19 Protein Subunit Recombinant VaccineBiological
SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
Active ComparatorBiological
Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immunogenicity of the candidate vaccineTime frame: 14 days after the last dose
- Seroconversion rate of the candidate vaccineTime frame: 14 days after the last dose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Faculty of Medicine Diponegoro University
Semarang, Central Java, Indonesia
Fakultas Kedokteran Universitas Indonesia
Jakarta, Greater Jakarta, Indonesia
Faculty of Medicine Universitas Hassanudin
Makassar, South Sulawesi, Indonesia
Faculty of Medicine Universitas Andalas
Padang, West Sumatera, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.